- Home
- EXOZ vs GALT Comparison
EXOZ vs GALT Comparison
Compare EXOZ & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXOZ
- GALT
- Stock Information
- Founded
- EXOZ 2014
- GALT 2000
- Country
- EXOZ United States
- GALT United States
- Employees
- EXOZ N/A
- GALT N/A
- Industry
- EXOZ
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- EXOZ
- GALT Health Care
- Exchange
- EXOZ NYSE
- GALT Nasdaq
- Market Cap
- EXOZ 89.8M
- GALT 86.0M
- IPO Year
- EXOZ N/A
- GALT N/A
- Fundamental
- Price
- EXOZ $14.55
- GALT $1.32
- Analyst Decision
- EXOZ
- GALT Hold
- Analyst Count
- EXOZ 0
- GALT 1
- Target Price
- EXOZ N/A
- GALT N/A
- AVG Volume (30 Days)
- EXOZ 13.7K
- GALT 140.7K
- Earning Date
- EXOZ 05-12-2025
- GALT 05-19-2025
- Dividend Yield
- EXOZ N/A
- GALT N/A
- EPS Growth
- EXOZ N/A
- GALT N/A
- EPS
- EXOZ N/A
- GALT N/A
- Revenue
- EXOZ N/A
- GALT N/A
- Revenue This Year
- EXOZ N/A
- GALT N/A
- Revenue Next Year
- EXOZ N/A
- GALT N/A
- P/E Ratio
- EXOZ N/A
- GALT N/A
- Revenue Growth
- EXOZ N/A
- GALT N/A
- 52 Week Low
- EXOZ $8.50
- GALT $0.73
- 52 Week High
- EXOZ $23.99
- GALT $3.41
- Technical
- Relative Strength Index (RSI)
- EXOZ N/A
- GALT 46.72
- Support Level
- EXOZ N/A
- GALT $1.34
- Resistance Level
- EXOZ N/A
- GALT $1.55
- Average True Range (ATR)
- EXOZ 0.00
- GALT 0.14
- MACD
- EXOZ 0.00
- GALT 0.01
- Stochastic Oscillator
- EXOZ 0.00
- GALT 22.50
About EXOZ EXOZYMES INC
EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.